Clinical Trials

Sling Therapeutics’ convenient oral small molecule linsitinib is in a Phase 2b trial for thyroid eye disease (TED).

Linsitinib works by inhibiting the validated IGF-1R target, and our partnered clinical sites are studying its use in TED (a list of participating sites can be found here at

Note: Linsitinib is not approved as a marketed product at this time. Clinical trials are required by the FDA to demonstrate the safety and efficacy of a potential medication before general availability.